Clinical Trial Update: Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating venetoclax in combination with chidamide and azacitidine (VCA) for relapsed/refractory acute myeloid leukemia is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Chidamide (chidamide)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Leukemia, Myeloid, Acute, Relapsed Adult AML | Phase 2 | Status: RECRUITING